Riceperidon, the drug used for the treatment of behavioral symptoms in patients with demicolis, increases the risk of palsy. This conclusion was researchers from the Brunel University of London. Their results were published in the magazine of British Journal of Psychiatry (BJP).
Riceperidon is an anti-leaft of patients who demonstrate severe aggression, especially when other approaches have failed. In the UK, this type of anti-thye drug is the only one who has been officially confirmed to use in the case of Demencies.
The authors analyzed the Anonymous data of the UK National Health Service (NHS) from 2004 to 2023. The study included a controlling group that did not receive Riceperido's patients.
The results showed that the risk of caselots (CVA) in survivors of the stroke was 22.2, a thousand people, compared to the disbursement of the drug, 17.7 per 1,000 people per year. In patients who do not have a history of stroke were also different. Patients who received Risperdon were about 1,000 people per year, and without it, 2.2.
Researchers also noted that the risk was higher with those who took the drug for a short period of time for 12 weeks. Current guidelines recommend Rosperidon to use no more than six weeks of severe symptoms, but in some cases it is used for longer, and monitoring methods differ from the region to the region.
"There are no other licensed drugs for the treatment of aggression in the UK, so patients and their families must be pre-informed about possible risks. The decision to use this medication must be made on an individual basis, taking into account the patient's medical history, "said one of the authors of the study, Dr. Julian Kriz.
Translation of: Euromedia24.com
